Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Withdrawn 1Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 2Oligodendroglioma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Astrocytoma 1Advanced Breast Cancer 1

Interventions

Cisplatin 38Carboplatin 28Gemcitabine 23Docetaxel 20Radiotherapy 18Etoposide 15Paclitaxel 13Erlotinib Hydrochloride 13Vinorelbine 11Drug Therapy 11pembrolizumab 9aumolertinib 9apatinib 9Pemetrexed 9Gefitinib 9osimertinib 7endostar protein 7Thoracic Surgery, Video-Assisted 7Blood Specimen Collection 7camrelizumab 6anlotinib 6Vinblastine 6Surgical Procedures, Operative 6sintilimab 5Radiosurgery 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5durvalumab 4Mitomycin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lung Neoplasms × In Situ Hybridization, Fluorescence × Clear all
NCT00989690 2013-08-12

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
275 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡